On the Horizon in NSCLC: Antibody Drug Conjugates - Episode 4

ADCs in NSCLC: Audience Q&A

,

Drs Edward S. Kim and Alexander Spira answer viewer questions on ADCs in non-small cell lung cancer.

EP. 1: ADC Technology and Mechanism of Action
EP. 2: ADCs in Non-Small Cell Lung Cancer
EP. 3: The Impact of ADCs on Non-Small Cell Lung Cancer Treatment
Now Viewing
EP. 4: ADCs in NSCLC: Audience Q&A

Sponsored by Daiichi Sankyo. Content independently developed by OncLive®.

Related Content:

On the Horizon in NSCLC: Antibody Drug ConjugatesWebinarsLung Cancer
OncLive’s September Roundup of Key FDA Approvals in Oncology
Patient-Centered Discussions Will Be Critical to Navigate Treatment Selection in EGFR+ NSCLC
FDA Approves Perioperative Nivolumab for Resectable NSCLC